Condition: Esophageal Squamous Cell Carcinoma · High Grade Serous Ovarian Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: IDEAYA Biosciences
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
This description comes directly from the study's public registry record.
IDEAYA Clinical Trials · 1-855-433-2246 · IDEAYAClinicalTrials@ideayabio.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| START New York Long Island, LLC | Lake Success, New York, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| NEXT Texas LLC - Austin | Austin, Texas, United States | Recruiting |
| START Dallas Fort Worth, LLC | Fort Worth, Texas, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
| NEXT Texas LLC - Houston | Houston, Texas, United States | Recruiting |
| NEXT Texas LLC - Dallas | Irving, Texas, United States | Recruiting |
| NEXT Texas LLC - San Antonio | San Antonio, Texas, United States | Recruiting |
| START San Antonio, LLC | San Antonio, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07503808